Skip to main navigation Skip to search Skip to main content

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients with Amyotrophic Lateral Sclerosis (ALS)

  • Mathers, Susan (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusFinished
Effective start/end date12/01/21 → 11/01/26

Keywords

  • clinical trial
  • treatment efficacy
  • treatment safety
  • amyotrophic lateral sclerosis

Clinical Trial Phase

  • Phase III (a & b)